drugset / Trial / NCT02335879
Phase III Clinical Study of Domestic Recombinant Human Follitropin for Injection to Treat WHO Class II Anovulation
Phase 3
Completed
534 enrolled
Changchun GeneScience Pharmaceutical Co., Ltd.
Peking University First Hospital · collabPeking University People's Hospital · collabQilu Hospital of Shandong University · collabReproductive & Genetic Hospital of CITIC-Xiangya · collabSecond Affiliated Hospital of Wenzhou Medical University · collabSecond Hospital of Jilin University · collabShengjing Hospital · collabThe First Affiliated Hospital of Dalian Medical University · collabUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · collab
NaSingle-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of Domestic Recombinant Human Follitropin (Gonal-F) for Injection for treatment of WHO Ⅱ anovulation (including polycystic ovarian syndrome \[PCOS\] subjects).
Timeline
- Start
- 2008-05
- Primary completion
- 2009-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gonal-f | Protein / enzyme biologic | — | — |